InteliCare Holdings Limited (ICR) AI Stock Analysis

• Market Cap: AU$11.19M
• Dividend Yield: N/A
• Average Volume (3M): 1.91M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.34
• Revenue Growth: 241.34%
• EPS Growth: 44.19%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 621,890,140
• 10 Day Avg. Volume: 3,223,113
• 30 Day Avg. Volume: 1,908,177
• PEG Ratio: 0.02
• Price to Book (P/B): -3.27
• Price to Sales (P/S): 2.85
• P/FCF Ratio: -1.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: AU$0.02 ▼(-15.00% Downside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is weighed down primarily by weak financial performance—negative gross profit, ongoing losses and cash burn, and negative equity that raises funding risk. Technicals add modest downside pressure with the price below key moving averages and a negative MACD, while valuation contributes limited support because a negative P/E and no dividend yield reduce usefulness and defensiveness.

Positive Factors

Revenue growth rebound

A strong FY2025 revenue rebound of +45.3% indicates improving market traction and demand for the company's offerings. Sustained top-line growth over multiple quarters can create a runway for operating leverage, support scale benefits, and make margin recovery achievable if cost structure is managed.

Free cash flow closely tracks net income

Free cash flow moving in line with net income suggests that losses are driven by real cash outflows rather than one-off accounting adjustments. This transparency improves cash forecasting, makes funding needs more predictable, and helps investors and creditors assess the company’s sustainable cash burn profile.

Moderate absolute debt level

A relatively small absolute debt burden reduces near-term interest obligations and refinancing pressure versus highly leveraged peers. Lower nominal debt provides some flexibility to pursue recapitalization or short-term financing solutions while working to restore equity and profitability.

Negative Factors

Persistent negative gross profit

Gross profit negative across reported years indicates the core unit economics do not cover direct costs. This is a structural issue that requires fundamental changes—pricing, cost base, or product mix—to achieve sustainable margins, making profitable scale materially more difficult.

Negative shareholders' equity

Negative shareholders’ equity reflects cumulative losses exceeding capital, heightening recapitalization and covenant risk. This condition limits financial flexibility, increases likelihood of dilutive equity raises or costly financing, and constrains strategic options over the medium term.

Ongoing operating cash burn

Persistent negative operating and free cash flow requires continual external funding to sustain operations. Combined with negative equity, ongoing cash burn raises execution and funding risk, potentially forcing spending cuts that could impair growth or delaying investments needed to reach profitability.

InteliCare Holdings Limited Business Overview & Revenue Model

Company Description

Intelicare Holdings Limited engages in the sale of a predictive analytics hardware and software package for use in the aged care and health industries in Australia. The company offers InteliLiving for seniors and people with disability; and produces monitoring solution for seniors and at-risk individuals. Intelicare Holdings Limited was founded in 2016 and is headquartered in Leederville, Australia.

InteliCare Holdings Limited Financial Statement Overview

Summary

Despite a strong FY2025 revenue rebound (+45.3% YoY), financial quality remains very weak: negative gross profit across all reported years, a large FY2025 net loss (-2.24m) with deeply negative net margin (-234.6%), persistent negative operating/free cash flow (FY2025 FCF -1.67m), and negative shareholders’ equity in FY2024–FY2025 (-0.83m), increasing financing/recapitalization risk.

Income Statement

Revenue rebounded strongly in FY2025 (up 45.3% YoY), but profitability remains very weak. Gross profit is negative across all reported years, and FY2025 still shows a large net loss (-2.24m) with deeply negative net margin (-234.6%), indicating the core cost structure is not yet scaling with revenue. Losses have narrowed versus FY2022–FY2023, but the business is still far from breakeven.

Balance Sheet

The balance sheet has deteriorated materially: shareholders’ equity turned negative in FY2024 and worsened in FY2025 (-0.83m), which reduces financial flexibility and increases recapitalization risk. Debt is moderate in absolute terms (0.72m in FY2025), but negative equity makes leverage metrics distorted and highlights that liabilities meaningfully outweigh the equity base. Total assets also declined from FY2020–FY2025, suggesting a shrinking asset base while losses persist.

Cash Flow

Cash generation remains a key weakness with consistently negative operating cash flow and free cash flow every year. FY2025 operating cash flow (-1.67m) and free cash flow (-1.67m) were slightly worse than FY2024, and free cash flow growth in FY2025 was negative (-9.2%). A positive is that free cash flow has roughly tracked net income (free cash flow to net income ~1.0), indicating losses are not being significantly masked by non-cash accounting—but the company still requires ongoing funding to sustain operations.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	945.45K	956.74K	280.29K	404.35K	429.85K	363.12K
Gross Profit	-1.24M	-1.09M	-1.79M	-2.69M	-2.75M	-1.99M
EBITDA	-2.70M	-2.16M	-3.02M	-2.89M	-3.78M	-4.24M
Net Income	-2.84M	-2.24M	-2.26M	-3.00M	-3.93M	-4.36M
Balance Sheet
Total Assets	1.64M	1.02M	1.52M	2.48M	2.88M	3.43M
Cash, Cash Equivalents and Short-Term Investments	1.05M	410.53K	834.20K	1.94M	2.27M	2.67M
Total Debt	1.09M	716.62K	612.39K	726.57K	18.25K	85.16K
Total Liabilities	1.86M	1.86M	1.69M	1.53M	1.34M	842.64K
Stockholders Equity	-222.63K	-833.17K	-168.32K	949.11K	1.54M	2.59M
Cash Flow
Free Cash Flow	-2.56M	-1.67M	-1.66M	-3.11M	-3.14M	-3.86M
Operating Cash Flow	-2.55M	-1.67M	-1.66M	-3.10M	-3.10M	-3.79M
Investing Cash Flow	-6.45K	-7.09K	0.00	-14.35K	-32.92K	-74.79K
Financing Cash Flow	2.35M	1.25M	555.65K	2.78M	2.73M	2.34M

InteliCare Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EMD	49 Neutral	AU$34.68M	-4.21	-52.26%	―	-36.68%	79.41%
ICR	44 Neutral	AU$11.19M	-2.48	-578.72%	―	241.34%	44.19%
HIQ	44 Neutral	AU$9.49M	-0.96	152.58%	―	-40.05%	-49.57%
TD1	43 Neutral	AU$2.24M	-1.11	-42.29%	―	―	78.95%
SHG	43 Neutral	AU$75.76M	-6.64	-59.96%	―	―	―
GLH	42 Neutral	AU$3.94M	-1.98	20.02%	―	-9.90%	34.07%

InteliCare Holdings Limited Corporate Events

InteliCare secures $8.8m mecwacare deal in largest aged care rollout

InteliCare has signed a five-year Master Subscription Agreement with Victorian not-for-profit provider mecwacare to roll out its analytics, IoT and integrated nurse call platform across 22 residential aged care facilities supporting about 1,600 residents. The deal, InteliCare’s largest to date with an estimated value of $8.8 million on full deployment, embeds the company as a key technology partner in mecwacare’s broader digital transformation strategy.

The agreement follows a successful pilot at mecwacare’s Trescowthick Centre, where InteliCare met or exceeded all 11 success criteria, including 100% fall detection accuracy and sharp reductions in overnight welfare checks. By consolidating clinical and operational data into a single intelligent dashboard and automating compliance reporting, the roll-out is expected to improve resident outcomes, boost staff efficiency and strengthen InteliCare’s competitive position in a rapidly evolving aged care market.

The most recent analyst rating on (AU:ICR) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InteliCare Holdings Limited stock, see the AU:ICR Stock Forecast page.

InteliCare Halts Trading Ahead of Strategic Partnership Announcement

InteliCare Holdings Limited has requested and been granted a trading halt on its securities by the ASX, effective 11 March 2026, as it prepares to release an announcement to the market. The halt will remain in place until either the commencement of normal trading on 13 March 2026 or the earlier release of the pending announcement.

The company says the halt is necessary while it finalises details of a material strategic partnership and long-term commercial agreement, which could have significant implications for its growth trajectory. The move signals a potentially important development in InteliCare’s commercial strategy and may influence investor sentiment once full details are disclosed.

The most recent analyst rating on (AU:ICR) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InteliCare Holdings Limited stock, see the AU:ICR Stock Forecast page.

InteliCare Half-Year Loss Widens as Revenue Dips and Balance Sheet Remains Weak

InteliCare Holdings Limited reported a weaker half-year result for the period ended 31 December 2025, with revenue from ordinary activities slipping 2.3% to $489,707 while its after-tax loss widened 77.1% to $1,367,939 compared with the prior corresponding period. The company did not declare any dividends and reported negative net tangible assets of 0.03 cents per share, underscoring ongoing financial pressure and highlighting the need for improved scale or funding to strengthen its balance sheet and progress toward sustainable operations.

The interim financial statements were reviewed by RSM Australia Partners, with the review report included in the company’s half-year financial report. The latest figures indicate that despite maintaining operations, InteliCare is still in a loss-making phase, which may concern investors focused on near-term profitability and capital position.

The most recent analyst rating on (AU:ICR) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InteliCare Holdings Limited stock, see the AU:ICR Stock Forecast page.

InteliCare Advances Aged-Care Deployments and Nears CEO Appointment

InteliCare reported steady operational progress in the December 2025 quarter, advancing commercial discussions with major aged care provider mecwacare toward a broader agreement to deploy its platform across 22 residential facilities and expanding its rollout within the Hardi Aged Care network, where implementation has begun at a fourth site, Seven Hills. The company has received around $980,000 of the $1.7 million in contracted hardware and implementation revenue from Hardi and is now collecting recurring SaaS fees from initial sites, while also strengthening its sales pipeline, enhancing product capabilities such as nurse call integration and real-time location features, and nearing completion of a CEO recruitment process to support its next phase of commercial growth and scale.

The most recent analyst rating on (AU:ICR) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on InteliCare Holdings Limited stock, see the AU:ICR Stock Forecast page.

InteliCare Posts Quarterly Cash Outflow but Ends December with Stronger Cash Balance

InteliCare Holdings Limited reported a net operating cash outflow of A$706,000 for the quarter ended 31 December 2025, with customer receipts of A$121,000 outweighed by staff, administration, manufacturing, and marketing expenses. The company offset these operating losses through financing activities, including A$180,000 in equity raised during the quarter and a total of A$2.0 million in equity proceeds plus A$400,000 in borrowings over the half year, resulting in a net increase in cash and cash equivalents and leaving InteliCare with A$1.75 million in cash at the end of the period, underscoring its continued dependence on external capital to sustain operations.

The most recent analyst rating on (AU:ICR) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on InteliCare Holdings Limited stock, see the AU:ICR Stock Forecast page.

InteliCare Confirms Compliance and Transparency on New Performance Rights Issue

InteliCare Holdings Limited has notified the market that it has issued performance rights and confirms it remains in full compliance with its financial reporting and continuous disclosure obligations under the Corporations Act. The company states there is no undisclosed price-sensitive information that investors or their advisers would reasonably require to assess its financial position, prospects, or the rights attached to its fully paid ordinary shares, reinforcing transparency around the new performance rights issuance for shareholders and the broader market.

The most recent analyst rating on (AU:ICR) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InteliCare Holdings Limited stock, see the AU:ICR Stock Forecast page.

InteliCare Plans Issue of 4.5 Million Performance Rights

InteliCare Holdings Limited has announced a proposed issue of up to 4.5 million performance rights (ASX code: ICRAP). The issue, structured as a placement or other type of securities issue and scheduled for 9 January 2026, signals the company’s intention to use equity-based instruments, likely as part of its capital management or incentive arrangements, with potential dilution implications for existing shareholders once the rights vest and convert into quoted securities.

The most recent analyst rating on (AU:ICR) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InteliCare Holdings Limited stock, see the AU:ICR Stock Forecast page.

InteliCare Director Increases Stake, Signaling Confidence in Growth

InteliCare Holdings Limited announced a change in the director’s interest, with Neale Fong acquiring an additional 4,500,000 performance rights, increasing his total to 18,500,000. This change, approved by shareholders at the AGM, indicates a strengthened commitment from the director, potentially impacting the company’s strategic direction and signaling confidence in its future growth.

InteliCare Holdings Limited Proposes New Securities Issue

InteliCare Holdings Limited announced a proposed issue of 15 million performance rights as part of a new securities placement. This move is likely aimed at strengthening the company’s financial position and supporting its strategic initiatives, potentially impacting its market presence and offering benefits to stakeholders.